GoodRx, Inc. (Nasdaq: GDRX), America’s leading resource for
healthcare savings, and Boehringer Ingelheim, a privately owned,
leading global biopharmaceutical company, today announced a new
joint effort to increase access to patient savings programs on the
GoodRx platform. Patients with type 2 diabetes or chronic
obstructive pulmonary disease (COPD) can now easily enroll in
manufacturer sponsored copay programs for Boehringer Ingelheim’s
leading portfolio of medications to help reduce their out-of-pocket
costs, with additional medications that may be added to the
integration in the future. This integration and proposed
integrations have the potential to deliver approximately $15
million in available savings a year for those that need
life-enhancing medications, based on internal estimates.
Diabetes affects 1 in 10 Americans (more than 10% of the U.S.
population), with 1.5 million people newly diagnosed each year,
according to the CDC. Access to diabetes medications is a critical
and often life-threatening part of ongoing treatment, and cost is a
barrier for many people with diabetes, with medical expenditures
approximately 2.3 times higher than they would be for people
without diabetes. The CDC also estimates COPD affects more than 16
million people and is the third leading cause of death by disease
in the U.S. The combined economic burden of both these conditions
is estimated to be more than $286 billion ($237 billion for
diabetes and $49 billion for COPD) in direct medical costs each
“As insurance deductibles increase, fewer medications are
covered by insurance, and more restrictions are placed on the
medications that are covered, patients are left carrying more of
the economic burden,” said Bansi Nagji, President of Healthcare at
GoodRx. “The integration of Boehringer Ingelheim savings programs
will help lower the affordability barrier for patients so they can
better access the medications they need.”
Consumers looking for manufacturer savings programs for diabetes
or COPD can go directly to the GoodRx website to find options
available from Boehringer Ingelheim. Those who qualify with
commercial insurance can find savings programs for their
prescription of Jardiance® (empagliflozin)*, Synjardy®
(empagliflozin/metformin HCI)*, Synjardy XR®
(empagliflozin/metformin HCI extended-release)*, Spiriva Respimat®
(tiotropium bromide), Stiolto Respimat® (tiotropium bromide and
olodaterol) and Combivent Respimat® (ipratropium bromide and
“The combination of Boehringer Ingelheim’s commitment to the
patients we serve and innovative approach to bringing
transformative therapies to market, and GoodRx’s trusted brand and
reach, means that we will be able to provide more patients with
seamless access to our support and savings programs,” said Chris
Marsh, Senior Vice President, Market Access, Boehringer Ingelheim
Pharmaceuticals, Inc. “We look forward to expanding our
collaborative partnership with GoodRx so we can help more people
living with chronic conditions find the appropriate savings program
that is right for them and lower their out-of-pocket costs.”
*products in the Boehringer Ingelheim and Eli Lilly and Company
About GoodRxGoodRx helps Americans get the
healthcare they need at a price they can afford. As America’s
leading resource for healthcare savings, GoodRx connects consumers
with affordable and convenient prescriptions and medical care,
including telehealth, mail order prescriptions, doctor visits, and
lab tests. We have helped Americans save over $30 billion since
2011 and are one of the most downloaded medical apps over the past
About Boehringer IngelheimBoehringer Ingelheim
is working on breakthrough therapies that improve the lives of
humans and animals. As a leading research-driven biopharmaceutical
company, the company creates value through innovation in areas of
high unmet medical need. Founded in 1885 and family-owned ever
since, Boehringer Ingelheim takes a long-term perspective. Around
52,000 employees serve more than 130 markets in the three business
areas, Human Pharma, Animal Health, and Biopharmaceutical Contract
Learn more at www.boehringer-ingelheim.us
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation statements regarding consumer savings. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the important factors
discussed under the caption “Risk Factors” in GoodRx’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2020, and
our other filings with the SEC. These factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
What is JARDIANCE? (www.jardiance.com)JARDIANCE
is a prescription medicine used along with diet and exercise to
lower blood sugar in adults with type 2 diabetes.
JARDIANCE is also used to reduce the risk of cardiovascular
death in adults with type 2 diabetes who have known cardiovascular
JARDIANCE is not for people with type 1 diabetes. It may
increase their risk of diabetic ketoacidosis (increased ketones in
the blood or urine).
JARDIANCE is not for use to lower blood sugar in adults with
type 2 diabetes who have severe kidney problems, because it may not
IMPORTANT SAFETY INFORMATIONDo not
take JARDIANCE if you are allergic to empagliflozin or any
of the ingredients in JARDIANCE.
Do not take JARDIANCE if you are on
JARDIANCE can cause serious side effects,
- Ketoacidosis (increased ketones in your blood or
urine). Ketoacidosis is a serious condition which needs to
be treated in the hospital. Ketoacidosis may lead to death.
Ketoacidosis occurs in people with type 1 diabetes and can also
occur in people with type 2 diabetes taking JARDIANCE, even
if blood sugar is less than 250 mg/dL. Ketoacidosis has
also happened in people with diabetes who were sick or who had
surgery during treatment with JARDIANCE. Stop taking
JARDIANCE and call your doctor right away or go to the nearest
hospital emergency room if you get any of the following
symptoms, and if possible, check for ketones in your
- stomach-area (abdominal) pain
- trouble breathing
- Dehydration. JARDIANCE can cause some people
to become dehydrated (the loss of body water and salt). Dehydration
may cause you to feel dizzy, faint, light-headed, or weak,
especially when you stand up. Sudden worsening of kidney function
has happened in people who are taking JARDIANCE.
You may be at a higher risk of dehydration if you:
- take medicines to lower your blood pressure, including water
- are on a low salt diet
- have kidney problems
- are 65 years of age or older
Talk to your doctor about what you can do to prevent
dehydration, including how much fluid you should drink on a daily
basis, and if you reduce the amount of food or liquid you drink, if
you are sick or cannot eat or start to lose liquids from your body
from vomiting, diarrhea, or being in the sun too long.
- Serious urinary tract infections. Serious
urinary tract infections can occur in people taking JARDIANCE and
may lead to hospitalization. Tell your doctor if you have symptoms
of a urinary tract infection, such as a burning feeling when
passing urine, a need to urinate often or right away, pain in the
lower part of your stomach or pelvis, or blood in the urine.
Sometimes people also may have a fever, back pain, nausea or
- Low blood sugar (hypoglycemia): If you take
JARDIANCE with another medicine that can cause low blood sugar,
such as sulfonylurea or insulin, your risk of low blood sugar is
higher. The dose of your sulfonylurea or insulin may need to be
lowered. Symptoms of low blood sugar may include:
- fast heartbeat
- shaking or feeling jittery
- Necrotizing fasciitis. A rare but serious bacterial
infection that causes damage to the tissue under the skin in the
area between and around your anus and genitals (perineum).
This bacterial infection has happened in women and men who take
JARDIANCE, and may lead to hospitalization, multiple surgeries, and
death. Seek medical attention immediately if you have fever
or are feeling very weak, tired or uncomfortable (malaise), and you
develop any of the following symptoms in the area between and
around your anus and genitals: pain or tenderness, swelling, and
redness of skin (erythema).
- Vaginal yeast infection. Talk to your doctor
if you have vaginal odor, white or yellowish vaginal discharge
(discharge may be lumpy or look like cottage cheese), and/or
- Yeast infection of the penis. Swelling of an
uncircumcised penis may develop that makes it difficult to pull
back the skin around the tip of the penis. Talk to your doctor if
you have redness, itching or swelling of the penis, rash of the
penis, foul smelling discharge from the penis, and/or pain in the
skin around penis.
- Allergic (hypersensitivity) reactions.
Symptoms of serious allergic reactions to JARDIANCE may include:
- swelling of your face, lips, throat and other areas of your
- difficulty with swallowing or breathing
- raised, red areas on your skin (hives)
If you have any of these symptoms, stop taking JARDIANCE and
contact your doctor or go to the nearest emergency room right
The most common side effects of JARDIANCE
include urinary tract infections and yeast infections in
These are not all the possible side effects of JARDIANCE. For
more information, ask your doctor or pharmacist.
Before taking JARDIANCE, tell your doctor about all of
your medical conditions, including if you:
- have kidney problems
- have liver problems
- have a history of infection of the vagina or penis
- have a history of urinary tract infections or problems with
- are going to have surgery. Your doctor may stop your JARDIANCE
before you have surgery. Talk to your doctor if you are having
surgery about when to stop taking JARDIANCE and when to start it
- are eating less or there is a change in your diet
- have or have had problems with your pancreas, including
pancreatitis or surgery on your pancreas
- drink alcohol very often, or drink a lot of alcohol in the
short term (“binge” drinking)
- have type 1 diabetes. JARDIANCE should not be used to treat
people with type 1 diabetes.
- are pregnant or plan to become pregnant. JARDIANCE may harm
your unborn baby. Tell your doctor right away if you become
pregnant during treatment with JARDIANCE
- are breastfeeding or are planning to breastfeed. JARDIANCE may
pass into your breast milk and may harm your baby. Do not
breastfeed while taking JARDIANCE
Tell your doctor about all the medicines you
take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. Especially
tell your doctor if you take water pills (diuretics) or
medicines that can lower your blood sugar, such as insulin.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call
For more information, please see Prescribing Information and
INDICATION FOR USE AND IMPORTANT SAFETY
COMBIVENT RESPIMAT (ipratropium bromide and albuterol)
Inhalation Spray is indicated for use in patients with chronic
obstructive pulmonary disease (COPD) on a regular aerosol
bronchodilator who continue to have evidence of bronchospasm
(airway narrowing) and who require a second bronchodilator.
IMPORTANT SAFETY INFORMATION
Do not use COMBIVENT RESPIMAT if you are allergic to any of the
ingredients in COMBIVENT RESPIMAT or to atropine or other similar
COMBIVENT RESPIMAT can cause the narrowing of the airways to get
worse (paradoxical bronchospasm) which may be life threatening. If
this happens, stop taking COMBIVENT RESPIMAT at once and call your
doctor or get emergency help.
COMBIVENT RESPIMAT can cause serious heart-related side effects,
such as palpitations, chest pain, rapid heart rate, high blood
pressure, tremor, or nervousness. Call your doctor if you
experience any of these symptoms.
Avoid spraying COMBIVENT RESPIMAT into your eyes. COMBIVENT
RESPIMAT may increase eye pressure which may cause or worsen some
types of glaucoma. If you have sudden vision changes, eye pain or
visual halos, stop taking COMBIVENT RESPIMAT and call your doctor
COMBIVENT RESPIMAT may cause difficulty with urination.
Dizziness and blurred vision may occur with COMBIVENT RESPIMAT.
Should you experience these symptoms, use caution when engaging in
activities such as driving a car or operating appliances or other
Do not use COMBIVENT RESPIMAT more often than your doctor has
directed. Deaths have been reported with similar inhaled medicines
in asthma patients who use the medicine too much. Seek medical
attention if your treatment with COMBIVENT RESPIMAT becomes less
effective for symptomatic relief, your symptoms become worse,
and/or you need to use the product more frequently than usual.
Allergic reactions may occur, including itching, swelling of the
face, lips, tongue, or throat (involving difficulty in breathing or
swallowing), rash, hives, bronchospasm (airway narrowing), or
anaphylaxis. Some of these may be serious. If you experience any of
these symptoms, stop taking COMBIVENT RESPIMAT at once and call
your doctor or get emergency help.
Tell your doctor about all your medical conditions, especially
if you have narrow-angle glaucoma, prostate or urinary problems, a
history of heart conditions (such as irregular heartbeat, high
blood pressure), thyroid disorder, or diabetes. Also tell your
doctor if you are pregnant or nursing.
Tell your doctor about all medicines you are taking, especially
heart medications or drugs to treat depression.
The most common side effects reported with use of COMBIVENT
RESPIMAT include infection of the ears, nose, and throat, runny
nose, cough, bronchitis, headache, and shortness of breath.
For full Prescribing Information visit www.combivent.com, ask
your doctor or pharmacist, or press zero to connect to a live
operator to request a copy of the Prescribing Information.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
IMPORTANT SAFETY INFORMATION
Do not use SPIRIVA RESPIMAT or SPIRIVA HANDIHALER if you are
allergic to tiotropium, ipratropium, atropine or similar drugs, or
any ingredient in these medicines.
SPIRIVA RESPIMAT or SPIRIVA HANDIHALER are not rescue medicines
and should not be used for treating sudden breathing problems. Your
doctor may give you other medicine to use for sudden breathing
SPIRIVA RESPIMAT or SPIRIVA HANDIHALER can cause allergic
reactions. Symptoms can include raised red patches on your skin
(hives), itching, rash and/or swelling of the lips, tongue, or
throat that may cause difficulty in breathing or swallowing. If you
have any of these symptoms, stop taking the medicine and seek
emergency medical care.
Before using SPIRIVA HANDIHALER, tell your doctor if you have a
severe allergy to milk proteins.
SPIRIVA RESPIMAT or SPIRIVA HANDIHALER can cause your breathing
to suddenly get worse (bronchospasm). If this happens, use your
rescue inhaler, stop taking SPIRIVA, and call your doctor right
away or seek emergency medical care.
SPIRIVA RESPIMAT or SPIRIVA HANDIHALER can increase the pressure
in your eyes (acute narrow-angle glaucoma) which can cause the
following symptoms: eye pain, blurred vision, seeing halos or
colored images along with red eyes. If you have any of these
symptoms, stop taking your medicine and call your doctor right
Dizziness and blurred vision may occur with SPIRIVA RESPIMAT or
SPIRIVA HANDIHALER. If you experience these symptoms, use caution
when engaging in activities such as driving a car, or operating
appliances or other machines.
SPIRIVA RESPIMAT or SPIRIVA HANDIHALER can cause new or worsened
urinary retention. Symptoms of blockage in your bladder and/or
enlarged prostate may include difficulty passing urine and/or
painful urination. If you have any of these symptoms, stop taking
your medicine and call your doctor right away.
The most common side effects reported with SPIRIVA RESPIMAT in
patients with COPD include sore throat, cough, dry mouth, and sinus
The most common side effects reported with SPIRIVA HANDIHALER in
patients with COPD include upper respiratory tract infection, dry
mouth, sinus infection, sore throat, non-specific chest pain,
urinary tract infection, indigestion, runny nose, constipation,
increased heart rate, and blurred vision.
Do not swallow SPIRIVA capsules. The contents of the capsule
should only be inhaled through your mouth using the HANDIHALER
Do not spray SPIRIVA RESPIMAT into your eyes, as this may cause
blurring of vision and pupil dilation.
Tell your doctor about all your medical conditions including
kidney problems, glaucoma, enlarged prostate, problems passing
urine, or blockage in your bladder.
Tell your doctor all the medicines you take, including eye
drops. Ask your doctor if you are taking any anticholinergic
medicines because taking them together with SPIRIVA can increase
side effects. Do not use SPIRIVA RESPIMAT and SPIRIVA HANDIHALER
SPIRIVA RESPIMAT, 2.5 mcg, and SPIRIVA HANDIHALER are long-term,
once-daily, prescription maintenance medicines used to control
symptoms of chronic obstructive pulmonary disease (COPD) by
relaxing your airways and keeping them open. COPD includes chronic
bronchitis and emphysema. SPIRIVA RESPIMAT and SPIRIVA HANDIHALER
also reduce the likelihood of flare-ups (COPD exacerbations).
SPIRIVA is not a treatment for sudden symptoms of COPD.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.
Historical Stock Chart
From Sep 2021 to Oct 2021
Historical Stock Chart
From Oct 2020 to Oct 2021